http://fdamedication.searchella.com Information on Nutrition and Medications Fri, 21 Nov 2008 19:55:21 +0000 http://backend.userland.com/rss092 en FRANKLIN LAKES, N.J., November 21, 2008 /PRNewswire-FirstCall/ -- Today, prescription drugs are the first choice for medical intervention in treating 88 percent of patients suffering chronic conditions. The 50 percent of Americans treated for a... http://fdamedication.searchella.com/2008/11/21/new-data-advanced-pharmacy-model-significantly-reduces-gaps-in-care-for-patients-with-chronic-and-complex-conditions-improves-clinical-and-financial-outcomes/ MONTVALE, N.J., November 21, 2008 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals... http://fdamedication.searchella.com/2008/11/21/barr-shareholders-approve-pending-teva-acquisition/ Contents of a Complete Submission for the Evaluation of Proprietary Names http://fdamedication.searchella.com/2008/11/21/guidance-for-industry-83/ A study showed that early HIV diagnosis and early antiretroviral therapy reduced early infant mortality and HIV progression each by about 75%. Medscape Medical News http://fdamedication.searchella.com/2008/11/21/early-hiv-diagnosis-therapy-may-reduce-early-infant-mortality-and-hiv-progression/ Adding lapatinib to paclitaxel for first-line treatment of metastatic breast cancer improves efficacy only in HER2-positive patients, according to an international study. Reuters Health Information http://fdamedication.searchella.com/2008/11/21/lapatinibpaclitaxel-helpful-only-in-her2-positive-breast-cancer/ There is no clear advantage to using etanercept for treatment of idiopathic pulmonary fibrosis (IPF), researchers report in the November 1st issue of the American Journal of Respiratory and Critical Care Medicine. Reuters Health Information http://fdamedication.searchella.com/2008/11/21/etanercept-of-no-clear-benefit-for-idiopathic-pulmonary-fibrosis/ In children with nocturnal enuresis who fail treatment with desmopressin, adding the anticholinergic agent tolterodine to therapy leads to a significant decrease in the risk of a bedwetting episode, Missouri-based researchers report in the November issue of Pediatrics. Reuters Health Information http://fdamedication.searchella.com/2008/11/21/anticholinergic-helps-desmopressin-curb-bedwetting/ As a shortage of Haemophilus influenzae type b (Hib) conjugate vaccines is expected to persist until mid-2009, clinicians are advised to increase their efforts to serotype and report all cases of invasive H. influenzae disease in young children. Reuters Health Information http://fdamedication.searchella.com/2008/11/21/hib-vaccine-shortage-in-us-makes-surveillance-critical/ PANOS brands, of Saddle Brook, NJ is recalling Vegan Rella Cheddar Block, (a cheese substitute) with a Sell by date of 12/09/2008. http://fdamedication.searchella.com/2008/11/21/panos-brands-recalls-vegan-rella-cheddar-block-november-21/ Most patients with HIV infection around the globe have HIV-1 subtypes other than type B. The current article reviews patterns of resistance and treatment response among these viral subtypes. Future HIV Therapy http://fdamedication.searchella.com/2008/11/21/drug-resistance-differences-among-hiv-types-and-subtypes-a-growing-problem-2/